Molecular Therapy: Methods & Clinical Development (Jan 2016)

Efficient detection of human circulating tumor cells without significant production of false-positive cells by a novel conditionally replicating adenovirus

  • Fuminori Sakurai,
  • Nobuhiro Narii,
  • Kyoko Tomita,
  • Shinsaku Togo,
  • Kazuhisa Takahashi,
  • Mitsuhiro Machitani,
  • Masashi Tachibana,
  • Masaaki Ouchi,
  • Nobuyoshi Katagiri,
  • Yasuo Urata,
  • Toshiyoshi Fujiwara,
  • Hiroyuki Mizuguchi

DOI
https://doi.org/10.1038/mtm.2016.1
Journal volume & issue
Vol. 3, no. C

Abstract

Read online

Circulating tumor cells (CTCs) are promising biomarkers in several cancers, and thus methods and apparatuses for their detection and quantification in the blood have been actively pursued. A novel CTC detection system using a green fluorescence protein (GFP)–expressing conditionally replicating adenovirus (Ad) (rAd-GFP) was recently developed; however, there is concern about the production of false-positive cells (GFP-positive normal blood cells) when using rAd-GFP, particularly at high titers. In addition, CTCs lacking or expressing low levels of coxsackievirus–adenovirus receptor (CAR) cannot be detected by rAd-GFP, because rAd-GFP is constructed based on Ad serotype 5, which recognizes CAR. In order to suppress the production of false-positive cells, sequences perfectly complementary to blood cell–specific microRNA, miR-142-3p, were incorporated into the 3′-untranslated region of the E1B and GFP genes. In addition, the fiber protein was replaced with that of Ad serotype 35, which recognizes human CD46, creating rAdF35-142T-GFP. rAdF35-142T-GFP efficiently labeled not only CAR-positive tumor cells but also CAR-negative tumor cells with GFP. The numbers of false-positive cells were dramatically lower for rAdF35-142T-GFP than for rAd-GFP. CTCs in the blood of cancer patients were detected by rAdF35-142T-GFP with a large reduction in false-positive cells.